Investigating how a specific mutation affects blood cell signaling in chronic blood disorders.
JAK2V617F transactivation of JAK1 mediates constitutive activation of IL-10R signaling
['FUNDING_FELLOWSHIP'] · UNIVERSITY OF CALIFORNIA-IRVINE · NIH-10998487
This study is looking at a specific gene mutation in people with Myeloproliferative Neoplasms (MPNs) to see how it affects blood cell behavior, with the hope of finding new ways to treat the condition and help patients feel better.
Quick facts
| Phase | ['FUNDING_FELLOWSHIP'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF CALIFORNIA-IRVINE (nih funded) |
| Locations | 1 site (IRVINE, UNITED STATES) |
| Trial ID | NIH-10998487 on ClinicalTrials.gov |
What this research studies
This research focuses on Myeloproliferative Neoplasms (MPNs), a group of chronic blood disorders characterized by the JAK2V617F mutation. The study aims to understand how this mutation leads to abnormal signaling in blood cells, particularly through the IL-10 receptor pathway, which is typically impaired in MPN patients. By using a specialized murine pro B-cell model, the researchers will analyze the mechanisms that allow these mutant cells to thrive despite the dysfunctional signaling. The goal is to identify new therapeutic targets that could help combat disease progression and improve patient outcomes.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with Myeloproliferative Neoplasms who have the JAK2V617F mutation.
Not a fit: Patients without the JAK2V617F mutation or those with other types of blood disorders may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that specifically target the mechanisms driving MPN, potentially improving survival and quality of life for patients.
How similar studies have performed: Previous research has shown promising results in targeting similar pathways in blood disorders, suggesting that this approach may yield beneficial outcomes.
Where this research is happening
IRVINE, UNITED STATES
- UNIVERSITY OF CALIFORNIA-IRVINE — IRVINE, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: WADLEY, WILLIAM LUCAS PAREDES — UNIVERSITY OF CALIFORNIA-IRVINE
- Study coordinator: WADLEY, WILLIAM LUCAS PAREDES
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.